The key finding
Researchers analyzed registration trials for all seven FDA-approved ADHD medications in adults and found meaningful differences in how these drugs cause side effects. Nonstimulant medications (like atomoxetine) were linked to a greater variety of side effect types, while stimulant medications (like amphetamine and methylphenidate) were associated with higher rates of occurrence for the side effects they did cause. Importantly, every medication showed at least some adverse events occurring in 1 out of every 10 participants. Despite these differences, overall discontinuation rates were similar across both stimulant and nonstimulant options, suggesting that while the pattern of side effects differs, they may be similarly tolerable overall.
What the study looked like
This 2024 systematic review examined data from FDA package labels and registration trials for all seven medications approved to treat ADHD in adults. The researchers analyzed adverse event reports from the clinical trials that pharmaceutical companies submitted to gain FDA approval. These trials included a mix of fixed-dose and flexible-dose study designs, where participants received either the ADHD medication or placebo. The research team conducted three specific analyses: they identified side effects occurring at rates of 1 in 5, 1 in 10, and 1 in 20 participants after adjusting for placebo effects; they examined which side effects were associated with participants stopping treatment; and they looked for adverse events unique to specific medications. This approach allowed them to compile the most comprehensive comparison of ADHD medication side effects in adults to date.
Why researchers think this happened
The researchers suggest that the different side effect patterns between stimulants and nonstimulants reflect their distinct mechanisms of action in the brain. Stimulant medications work primarily by increasing dopamine and norepinephrine quickly and directly, which may explain why their side effects occur more frequently but in more predictable patterns. Nonstimulant medications affect neurotransmitter systems through different pathways and often take longer to reach full effect, potentially leading to a wider variety of side effects across different body systems. The authors note that this represents the first time anyone has systematically compiled adverse event data across all FDA registration trials for adult ADHD medications, filling an important gap in the available evidence. They built on prior work examining individual medications but extended it to create a comprehensive comparison that clinicians and patients could actually use when making treatment decisions.
How to read this carefully
Several limitations require careful interpretation of these findings. The registration trials included in this analysis used different methodologies and reported outcomes in varying ways, which may limit how well we can directly compare medications. The studies were designed to gain FDA approval rather than to compare medications head-to-head, so differences might partly reflect study design rather than true medication differences. Additionally, the trials were relatively short-term, so they may not capture side effects that emerge with longer use. The participants in registration trials may not fully represent the diversity of adults with ADHD in real-world settings—trial participants are often healthier and have fewer complicating conditions than typical patients. It’s also important to remember that these data show associations between medications and side effects, not definitive causal relationships for every individual person.
What this means for everyday life
For adults considering ADHD medication or those already taking it, this research offers a framework for more informed conversations with healthcare providers. Given that nonstimulants show more varied side effect types while stimulants show higher frequency of certain effects, patients might consider which pattern matters more to them personally. Someone particularly sensitive to common side effects might lean toward options with lower occurrence rates, while someone worried about experiencing unexpected symptoms might prefer medications with more predictable side effect profiles. The finding that discontinuation rates were similar across medications is reassuring—it suggests that while side effects differ, most people find ways to manage them regardless of which medication they choose. This research highlights that treatment decisions can be personalized beyond just effectiveness, incorporating individual preferences about side effect patterns into the shared decision-making process.